Oncolytics Biotech
ONCY
44 hedge funds and large institutions have $3.39M invested in Oncolytics Biotech in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
7% more funds holding
Funds holding: 41 → 44 (+3)
0.01% less ownership
Funds ownership: 2.04% → 2.03% (-0.01%)
12% less capital invested
Capital invested by funds: $3.87M → $3.39M (-$474K)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$289K |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$159K |
| 3 |
VF
Virtu Financial
New York
|
+$109K |
| 4 |
Two Sigma Investments
New York
|
+$77.2K |
| 5 |
Renaissance Technologies
New York
|
+$70.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$648K |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$355K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$61.2K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$60.8K |
| 5 |
Squarepoint
New York
|
-$44K |
ONCY Hedge Fund Activity: Q2 2021 in Review
44 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2021, worth a combined $3.39M — down 12% from $3.87M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ONCY positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $289K. The largest seller was Creative Planning, exiting entirely with an estimated $648K sold.
- 44 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $3.39M of Oncolytics Biotech stock for Q2 2021, down 12% quarter-over-quarter.
- 8 funds opened new Oncolytics Biotech positions in Q2 2021 and 5 closed out, a net change of +3 holders.
- The largest Oncolytics Biotech buyer in Q2 2021 was JP Morgan Chase, an estimated $289K added.
- The largest Oncolytics Biotech seller in Q2 2021 was Creative Planning, an estimated $648K sold.
Based on aggregated 13F filings for Q2 2021.